// App-Quantinova.ai

OP0249 (2021) : SERUM PROTEOMIC BIOMARKERS DEFINE PATIENTS WITH SYSTEMIC SCLEROSIS WITH INTERSTITIAL LUNG DISEASE

Researchers

Presenter

  • M. De Santis

Principal Investigators

  • N. Isailovic

  • A. Ceribelli

  • F. Motta

  • M. Vecellio

  • C. Selmi

Medical Centers

  • Humanitas Clinical and Research Center- IRCCS, Rheumatology and Clinical Immunology, Rozzano, Italy

  • Humanitas University, Department of Biomedical Sciences, Rozzano, Italy

  • University of Oxford Botnar Research Centre, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

Locations

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Pulmonary/Respiratory Diseases

Disease

  • Interstitial lung disease

  • Scleroderma

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved